(3-甲酰基苯基)-氨基甲酸叔丁酯 | 176980-36-2

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-甲酰基苯基)-氨基甲酸叔丁酯
• 中文别名: 3-(叔丁氧羰基氨基)苯甲醛
• 英文名称: tert-butyl (3-formylphenyl)carbamate
• 英文别名: (3-formylphenyl)carbamic acid tert-butyl ester；3-(tert-butoxycarbonylamino)benzaldehyde；tert-butyl N-(3-formylphenyl)carbamate；3-(Boc-amino)benzaldehyde
• CAS: 176980-36-2
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: JEUBPGIHGQWLAJ-UHFFFAOYSA-N

物化性质

• 熔点：
  88℃
• 沸点：
  291℃
• 密度：
  1.163
• 闪点：
  130℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090
• 储存条件：
  温度：2-8°C，保持在惰性气体氛围中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(BOC-Amino)benzaldehyde
Synonyms: (3-Formyl-phenyl)-carbamic acid tert-butyl ester

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(BOC-Amino)benzaldehyde
CAS number: 176980-36-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H15NO3
Molecular weight: 221.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-甲酰基苯基)-氨基甲酸叔丁酯 在 甲醇 、 sodium tetrahydroborate 、 正丁基锂 、 sodium hydride 、 戴斯-马丁氧化剂 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.5h， 生成 N-((3-(methylamino)phenyl)(p-tolyl)methyl)-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carboxamide
  参考文献：
  名称：

  [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF
  [FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。

  公开号：

  WO2021003295A1
• 作为产物：
  描述：

  3-(N-boc-氨基)苄醇 在 manganese(IV) oxide 作用下， 以 二氯甲烷 为溶剂， 反应 168.0h， 以59%的产率得到(3-甲酰基苯基)-氨基甲酸叔丁酯
  参考文献：
  名称：

  在碱性条件下由醛和醇制备缩醛†

  摘要：

  已经报道了在碱性条件下由不可烯化的醛和醇合成乙缩醛的一种新的，简单的方案。醇钠与相应的三氟乙酸酯一起促进了这种反应，利用三氟乙酸钠的形成作为缩醛形成的驱动力。通过与各种酸敏感保护基团的正交性以及与官能团的良好相容性，证明该方案的实用性，在酸性条件下由醛类和醇类合成时，可提供合成有用的乙缩醛以补充合成。

  DOI：

  10.1039/c8ob00017d

文献信息

• Selective reduction of carboxylic acids to aldehydes with hydrosilane via photoredox catalysis
  作者：Muliang Zhang、Nan Li、Xingyu Tao、Rehanguli Ruzi、Shouyun Yu、Chengjian Zhu

  DOI：10.1039/c7cc05570f

  日期：——

  The direct reduction of carboxylic acids to aldehydes with hydrosilane was achieved through visible light photoredox catalysis. The combination of both single electron transfer and hydrogen atom transfer steps offers a novel and convenient approach to selective reduction of carboxylic acids to aldehydes. The method also features mild conditions, high yields, broad substrate scope, and good functional

  通过可见光光氧化还原催化可将羧酸与氢硅烷直接还原为醛。单电子转移步骤和氢原子转移步骤的结合提供了一种新颖且方便的方法，用于将羧酸选择性还原为醛。该方法还具有温和的条件，高收率，广泛的底物范围和良好的官能团耐受性，例如炔烃基，酯基，酮基，酰胺基和胺基。
• Accessing Difluoromethylated and Trifluoromethylated <i>cis</i> ‐Cycloalkanes and Saturated Heterocycles: Preferential Hydrogen Addition to the Substitution Sites for Dearomatization
  作者：Xue Zhang、Liang Ling、Meiming Luo、Xiaoming Zeng

  DOI：10.1002/anie.201907457

  日期：2019.11.18

  Reported here is a straightforward process in which a cyclic (alkyl)(amino)carbene/Rh catalyst system facilitates the preferential addition of hydrogen to the substitution sites of difluoromethylated and trifluoromethylated arenes and heteroarenes, leading to dearomative reduction. This strategy enables the diastereoselective synthesis of cis-difluoromethylated and cis-trifluoromethylated cycloalkanes

  此处报道的是一种简单的方法，其中环状（烷基）（氨基）卡宾/ Rh催化剂体系有助于将氢优先添加到二氟甲基化和三氟甲基化的芳烃和杂芳烃的取代位上，从而导致脱芳族还原反应。该策略使非对映选择性合成顺式-二氟甲基化和顺式-三氟甲基化的环烷烃和饱和的杂环，甚至允许形成具有定义的赤道取向的二-和三氟甲基的全顺式多-三氟甲基化的环状产物。氘标记研究表明，氢优先攻击平面芳烃的取代位，从而导致脱芳香化作用，可能以异质Rh为反应性物种，
• Photoinitiated carbonyl-metathesis: deoxygenative reductive olefination of aromatic aldehydes <i>via</i> photoredox catalysis
  作者：Shun Wang、Nanjundappa Lokesh、Johnny Hioe、Ruth M. Gschwind、Burkhard König

  DOI：10.1039/c9sc00711c

  日期：——

  carbonyl groups in a single reaction are less explored. Here, we report a photoredox-catalysis that uses B2pin2 as terminal reductant and oxygen trap allowing for deoxygenative olefination of aromatic aldehydes under mild conditions. This strategy provides access to a diverse range of symmetrical and unsymmetrical alkenes with moderate to high yield (up to 83%) and functional-group tolerance. To follow

  羰基-羰基烯化反应，即 McMurry 反应，代表了构建烯烃的有力策略。然而，在单个反应中直接偶联两个羰基的催化变体的探索较少。在这里，我们报告了一种使用 B 2 pin 2的光氧化还原催化作为末端还原剂和氧阱，允许在温和条件下对芳族醛进行脱氧烯化。该策略提供了获得各种对称和不对称烯烃的途径，具有中等至高产率（高达 83%）和官能团耐受性。为了遵循反应途径，进行了一系列实验，包括自由基抑制、氘标记、荧光猝灭和循环伏安法。此外，结合 NMR 研究和 DFT 计算来检测和分析三种活性中间体：环状三元阴离子物质、α-氧硼基碳负离子和 1,1-苄基二硼酸酯。基于这些结果，我们提出了一种 C C 键生成机制，涉及顺序自由基硼化、“bora-Brook”重排、B 2pin 2介导的脱氧和硼-维蒂希过程。
• [EN] ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162293A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够与靶标结合的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的应用。
• CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER
  申请人：Pierre Fabre Medicament

  公开号：US20170112943A1

  公开（公告）日：2017-04-27

  The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

  本发明涉及一种抗体药物偶联物或包含该偶联物的药物组合物。从一方面来说，该发明涉及一种抗体药物偶联物（ADC），包括一种由曲妥珠单抗或其生物类似物组成的抗体，所述抗体与至少一种由单甲基奥瑞他汀F衍生物组成的药物偶联。该发明还包括一种治疗癌症的方法，包括向受试者施用有效量的所述抗体药物偶联物或包含该偶联物的组合物。